Effect of clonidine and yohimbine on sleep in healthy men: a double-blind, randomized, controlled trial

Eur J Clin Pharmacol. 1996;50(6):463-5. doi: 10.1007/s002280050141.

Abstract

Objective: To study the acute effect of clonidine, an alpha 2-adrenoceptor agonist, and yohimbine, an alpha 2-adrenoceptor antagonist, on nocturnal sleep in healthy men.

Setting: McGuire Veteran Affairs Medical Center, Richmond, Virginia, USA.

Subjects: Eight healthy male volunteers.

Methods: Each subject slept in the sleep laboratory for 2 consecutive nights on three separate sessions, at 3-week intervals. On the 2nd night of each session, the subjects received yohimbine (5.4 mg), clonidine (0.1 mg), or placebo in a double-blind, randomized, placebo-controlled, crossover design.

Results: There were no apparent effects of yohimbine. In contrast, clonidine completely suppressed rapid eye movement (REM) sleep in one subject and reduced REM sleep in the remaining seven subjects.

Conclusion: Our study confirms that clonidine markedly decreases REM, even at a low single dose, and supports the hypothesis of the important role of alpha 2-receptors in controlling REM sleep.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adrenergic alpha-Agonists / pharmacology*
  • Adrenergic alpha-Antagonists / pharmacology*
  • Adult
  • Clonidine / pharmacology*
  • Double-Blind Method
  • Humans
  • Male
  • Middle Aged
  • Sleep, REM / drug effects*
  • Yohimbine / pharmacology*

Substances

  • Adrenergic alpha-Agonists
  • Adrenergic alpha-Antagonists
  • Yohimbine
  • Clonidine